Highest-materiality recent filing
HealthEquity shareholders approve all five proposals at 2026 annual meeting
All ten director nominees elected with >74M votes each; no director received less than 95% support.
HealthEquity Q1 net income up 29%, raises FY2027 guidance, adds $1B buyback
Revenue $354.6M (+7% YoY); net income $69.4M ($0.82 dil. EPS, +34% YoY); non-GAAP EPS $1.24.
HealthEquity amends severance and equity vesting for six top officers
CEO Scott Cutler gets enhanced severance: 12 months base plus target bonus; 18 months base + 150% bonus if termination within 18 mo post-change-in-control.
HealthEquity terminates CTO Eli Rosner without cause; Rajasekar to oversee tech
Eli Rosner's employment as CTO terminated without cause effective April 17, 2026.
HealthEquity adds Sanford Health CEO Bill Gassen to board
William Gassen appointed to HealthEquity board, effective March 26, 2026.
HealthEquity reports record revenue; raises FY2027 guidance after strong Q4
FY2026 revenue $1.31B (+9% YoY); net income $215.2M (+123% YoY); EPS $2.46.
HealthEquity reports record Q4 HSA sales; total HSAs up 7% to 10.6M
Total HSAs: 10.6M as of Jan 31, 2026, +7% YoY; new HSAs from sales in Q4: 553K, +17% YoY.
HealthEquity initiates FY2027 guidance: revenue $1.38-1.41B, Adj. EBITDA margin 43.8-44.3%
FY2027 revenue guidance $1.38B-$1.41B; Adjusted EBITDA margin 43.8%-44.3%; HSA cash yield ~3.75%.
HealthEquity Q3 revenue $322M (+7%); net income $0.59 EPS; FY2026 guidance reaffirmed
Revenue $322.2M, up 7% YoY; custodial $159.1M, service $120.3M, interchange $42.8M.
Revenue $325.8M (+9% YoY); net income $59.9M ($0.68 diluted EPS) vs $35.8M ($0.40) in Q2 FY25.
HealthEquity board authorizes new $300M stock repurchase program
Board authorized new $300M stock repurchase program on June 26, 2025.
HealthEquity Q1 revenue $330.8M (+15% YoY), net income up 87%, raises FY2026 guidance
Revenue $330.8M (+15% YoY); net income $53.9M ($0.61 diluted EPS), +87% vs $28.8M.
HealthEquity announces departure of two directors; Black resigns, Kessler retires
Paul Black resigned from the Board on April 22, 2025; no disagreement with the Company.
HealthEquity FY25 revenue $1.2B (+20% YoY); net income up 74%; guides FY26 above consensus
FY25 revenue $1.20B (+20% YoY); net income $96.7M ($1.09 dilution) vs $55.7M; adjusted EBITDA $471.8M (+28%).
HealthEquity reports 14% HSA growth to 9.9M, $32.1B in assets, affirms FY25/FY26 outlook
Total HSAs reached 9.9M as of Jan 31, 2025, up 14% YoY from 8.7M.
HealthEquity reports record HSA sales: 9.8M HSAs, $31B assets, nearly 1M new HSAs
Estimated HSAs 9.8M as of Jan 31, 2025, up from 8.7M a year ago (12.6% growth).
HealthEquity Q3 revenue $300.4M (+21% YoY); non-GAAP EPS $0.78 vs $0.60; raises FY2025 outlook
Revenue $300.4M (+21% YoY); net income $5.7M ($0.06 diluted EPS) vs $14.7M ($0.17) prior.
HealthEquity settles lease lawsuit with Union Mesa for $32.8M
Union Mesa retained $2.8M letter of credit; HealthEquity/WageWorks to pay additional $30M.
HealthEquity CEO Jon Kessler to retire Jan 6, 2025; Scott Cutler appointed as successor
CEO Jon Kessler to retire effective Jan 6, 2025, serve as Special Advisor through Apr 30, 2025.
HealthEquity Q2 revenue up 23% to $299.9M; EPS $0.40; raises guidance, $300M buyback
Revenue $299.9M, +23% YoY; net income $35.8M ($0.40 diluted EPS) vs $10.6M ($0.12) last year.
HealthEquity enters $1B credit facility, repays prior $512M debt
New $1,000,000,000 senior secured revolving credit facility entered Aug 23, 2024; $511.9M drawn to refinance prior debt.
HealthEquity discloses data breach via compromised business partner account; PII/PHI accessed
A third party compromised a business partner's account, accessing personally identifiable and protected health information of some members.
HealthEquity stockholders approve 2024 Equity Incentive Plan with 4.085M new shares
Stockholders approved the 2024 Equity Incentive Plan; 4,085,000 shares authorized for future awards.
HealthEquity Q1 revenue $287.6M (+18% YoY), net income $28.8M; raises FY25 outlook
Revenue $287.6M, up 18% YoY; net income $28.8M ($0.33 diluted EPS) vs $4.1M ($0.05) in Q1 FY24.
HealthEquity issues 2024 Corporate Social Responsibility Report
Issued 2024 Corporate Social Responsibility Report on May 28, 2024.
HealthEquity completes $425M BenefitWallet acquisition; adds 616K HSAs, $2.7B in assets
Acquired ~616,000 HSAs and $2.7B in HSA assets from Conduent for $425M; funded with $225M revolver and cash.
Frank Corvino not to stand for re-election; board size reduced to 10
Frank Corvino notified the Board on April 25, 2024 he will not stand for re-election at the 2024 Annual Meeting.
HealthEquity completes 2nd tranche of Conduent HSA acquisition, adds 134k accounts, $555M assets
Second of three HSA asset transfers closed on April 11, 2024: 134,000 accounts and $555M in assets moved to HealthEquity.
FY 2024 revenue $999.6M (+16% YoY); net income $55.7M vs loss $26.1M; GAAP EPS $0.64 vs -$0.31.
HealthEquity completes first tranche of Conduent HSA portfolio acquisition
First tranche closed March 7: ~266,000 HSAs and $1.1B of assets transferred to HealthEquity.
HealthEquity reports 9% HSA growth to 8.7M accounts, raises FY24 guidance, affirms FY25 outlook
HSAs 8.69M (+9% YoY); HSA Assets $25.2B (+14%); Total Accounts 15.7M (+5%).
HealthEquity guides FY2024 year-end: ~8.7M HSAs, $24.5B HSA assets
Estimated HSAs ~8.7M as of Jan 31, 2024, up from 8.0M a year earlier (8.75% growth).
Revenue $249.2M (+15% YoY); net income $14.7M vs net loss $1.6M prior year.
HealthEquity to acquire BenefitWallet HSA portfolio from Conduent for $425M
Purchase price $425M for ~665,000 HSA accounts with ~$2.7B in assets.
HealthEquity Q2 revenue $243.5M (+18% YoY), net income $10.6M vs loss, EPS $0.53 non-GAAP
Revenue $243.5M, up 18% YoY from $206.1M; net income $10.6M vs net loss $10.7M in prior year.
HealthEquity terminates EVP and CSO Larry Trittschuh without cause effective July 28, 2023
HealthEquity terminated employment of Larry Trittschuh, EVP and Chief Security Officer, effective July 28, 2023, without cause.
HealthEquity CFO Tyson Murdock to depart after Aug 2023 10-Q filing; receives $100k retention bonus
CFO Tyson Murdock will cease as CFO following filing of Q2 FY2024 10-Q, expected in early September 2023.
All 11 director nominees elected with >74.4M votes for each; broker non-votes of ~3.58M.
HealthEquity names James Lucania as CFO; $575k salary, $4.5M RSU grant
James Lucania appointed EVP & CFO, starting Sept 2023 after Q2 10-Q filing.
HealthEquity Q1 revenue $244.4M (+19%), net income $4.1M vs loss, raises FY guidance
Revenue $244.4M (+19% YoY); GAAP EPS $0.05; non-GAAP EPS $0.50 vs $0.27.
HealthEquity amends credit agreement to replace LIBOR with Term SOFR
Amendment replaces LIBOR with Term SOFR plus 0.10% credit spread adjustment; margin range unchanged at 1.25%–2.25%.
Director Ian Sacks to not stand for re-election at HealthEquity 2023 annual meeting
Director Ian Sacks notified HealthEquity Board on April 13, 2023 of decision not to stand for re-election at 2023 Annual Meeting.
HealthEquity FY2023 revenue $861.7M (+14% YoY); guides FY2024 rev $960-975M, EBITDA $320-335M
Q4 revenue $233.8M (+15% YoY); net loss $0.2M vs $32.8M loss; non-GAAP EPS $0.37 vs $0.20.
HealthEquity discloses minimal SVB exposure; expects full access to funds
No HSA custodial cash deposited with Silicon Valley Bank.
HealthEquity reports record HSA sales of 971k new HSAs in FY23; assets up 13% to $22.1B
8.0M total HSAs (+11% YoY); Total Accounts 14.9M (+4% YoY).
HealthEquity amends bylaws to implement universal proxy card rules and other governance updates
Board adopted amendments on February 10, 2023, covering proxy card rules and stockholder meeting procedures.
HealthEquity estimates ~8M HSAs, $22B assets by Jan 31; record new account openings
Estimated 8 million HSAs by Jan 31, 2023, up from 7.2 million a year earlier.
HealthEquity Q3 revenue $216.1M (+20% YoY); narrows net loss; guides FY2024 ~$950-970M
Revenue $216.1M (+20% YoY); net loss $1.6M vs $5.0M loss; non-GAAP diluted EPS $0.38 vs $0.35.
HealthEquity Q2 revenue up 9% to $206.1M, net loss widens to $10.7M; guides FY23 revenue $834-844M
Revenue $206.1M (+9% YoY); net loss $10.7M vs $3.8M; non-GAAP net income $28.1M, down 16% from $33.4M.
HealthEquity appoints former Allscripts CEO Paul Black to board
Paul Black appointed to board effective Sept. 1, 2022; board expands to 12 members.
In addition, on April 30, 2025, the size of the Board will be further reduced to nine members following the previously announced retirement of Jon Kessler from the Board.
On April 22, 2025, Paul Black resigned as a member of the Board of Directors (the “Board”) of HealthEquity, Inc. (the “Company”).
the Board approved the appointment of Scott R. Cutler as President and Chief Executive Officer, effective as of January 6, 2025
will retire from his employment with the Company, effective January 6, 2025, and from the Board, effective April 30, 2025
the Board also expanded the size of the Board to eleven directors and appointed Mr. Cutler to fill the vacancy created by the increased size of the Board, each effective as of the Commencement Date
Jon Kessler, President & Chief Executive Officer of the Company and a member of the Board of Directors (the “Board”), will retire from his employment with the Company, effective January 6, 2025
Frank Corvino, who on April 25, 2024 notified the Board of his decision not to stand for re-election at the 2024 Annual Meeting of Stockholders.
On July 28, 2023, HealthEquity, Inc. (the “Company”) announced the termination of the employment of Larry Trittschuh, the Company’s Executive Vice President and Chief Security Officer, without cause and effective immediately.
Tyson Murdock will cease serving as Chief Financial Officer following the filing of the Company’s Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (the “SEC”) for the fiscal quarter ending July 31, 2023.
On June 14, 2023, HealthEquity, Inc. (the “Company”) announced that James M. Lucania will be appointed as the Company’s new Executive Vice President and Chief Financial Officer.
Ian Sacks, who on April 13, 2023 notified the Board of his decision not to stand for re-election at the 2023 Annual Meeting of Stockholders.
On September 1, 2022, the board of directors (the “Board”) of HealthEquity, Inc. (the “Company”) announced the appointment of Paul Black as a member of the Board, effective immediately.
Max materiality 0.85 · Median 0.68 · Most common event earnings